Adagio medical announces strategic restructuring to accelerate us pivotal ide trial and product innovation

Laguna hills, calif.--(business wire)--adagio medical holdings, inc. (nasdaq: adgm; the “company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced a corporate restructuring and realignment of resources to prioritize its fulcrum-vt us pivotal investigational device exemption (“pivotal ide”) clinical trial activities and its new product design optimization program. “after a comprehensive strategic review, we are doubling down on the pri.
ADGM Ratings Summary
ADGM Quant Ranking